The first and only NMDA receptor antagonist approved in conjunction with an oral AD for TRD in adults¹

SPRAVATO™ hypothesized mechanism of action

When administered in conjunction with an oral antidepressant,

SPRAVATO™ demonstrated efficacy in treatment-resistant depression in adults1

Superior improvement in depression symptoms at Week 41

Short-term efficacy

Significantly delayed time to relapse in a long-term study1

Long-term efficacy

SPRAVATO™ demonstrated safety in short- and long-term studies1

The most commonly observed adverse reactions*
  • Dissociation
  • Dizziness
  • Nausea
  • Sedation
  • Vertigo
  • Hypoesthesia
  • Anxiety
  • Lethargy
  • Blood pressure increased
  • Vomiting
  • Feeling drunk

*Incidence ≥5% and at least twice that of placebo plus oral antidepressant.

SPRAVATO™ does not require daily dosing

SPRAVATO™ should be administered in conjunction with an oral antidepressant¹

Learn more

Janssen CarePath

Your one source for Access, Affordability, and Treatment Support for your patients

Learn more

Find a Certified SPRAVATO™ Treatment Center

Learn more

Become a Certified SPRAVATO™ Treatment Center

Learn more

Reference

1. SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. May 2019.